BeOne Medicines' Beqalzi (sonrotoclax) receives FDA accelerated approval for relapsed or refractory mantle cell lymphoma as first BCL-2 inhibitor | Gif: hyperrpg on Giphy

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

BeOne Medicines' Beqalzi (sonrotoclax) receives FDA accelerated approval for relapsed or refractory mantle cell lymphoma as first BCL-2 inhibitor
Small molecule, cancer, BCL-2 inhibitor, mantle cell lymphoma, relapsed or refractory, BTK inhibitor - Read more

Taiho Oncology's Inqovi (decitabine and cedazuridine) plus venetoclax gains FDA approval for newly diagnosed acute myeloid leukemia
Small molecule, cancer, combination therapy, acute myeloid leukemia, BCL-2 inhibitor, hypomethylating agent - Read more

THE GOOD
Business Development & Partnerships

AstraZeneca, Owkin ink three-year agentic AI licensing deal for research and competitive intelligence automation
Licensing deal, AI/ML, drug discovery, R&D, data analytics - Read more

Fosun Pharma pays $60M for option on AriBio's phase 3 Alzheimer's asset AR1001, with $80M option fee
Licensing deal, neurological, small molecule, milestone payments - Read more

Cantex Pharmaceuticals, Headlamp Health partner to identify MS responders for azeliragon using agentic AI
Research collaboration, neurological, AI/ML, small molecule, drug discovery - Read more

Fangzhou, Tenry Pharmaceutical partner to advance AI-powered chronic disease management via GLP-1 therapy platform
Strategic partnership, AI/ML, chronic disease, digital health, small molecule, commercialization - Read more

PRESENTED BY SCIENCE 2 SALES
Outbound and commercial intelligence built exclusively for selling into biopharma.

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

✅ More Good News ✅

THE GOOD
Clinical Trials

Novo Nordisk's oral semaglutide delivers up to 21.6% weight loss in Ph3 obesity trial
Small molecule, metabolic, GLP-1 receptor agonist, obesity, oral semaglutide - Read more

Encoded Therapeutics' ETX101 shows durable seizure reduction in Ph1/2 for SCN1A-positive Dravet syndrome
Gene therapy, neurological, AAV gene therapy, Dravet syndrome, SCN1A, epilepsy - Read more

THE GOOD
Fundraises

Shanghai Yiminokang Biotechnology raises 250M yuan ($36.78M) Series A for antibody discovery platforms
Antibody discovery, AI/ML platform, CRISPR, gene editing, platform technology - Read more

QuartzBio receives undisclosed growth investment from Eir Partners for platform expansion
Software platform, biomarker discovery, AI-driven, clinical-stage, data analytics - Read more

SwishX raises $2.2M seed funding for agentic AI platform serving pharma operations
AI/ML platform, software platform, pharmaceutical, medtech, services - Read more

Autoimmunity BioSolutions raises $1M Seed Extension, advancing personalized genetically-guided immuno-corrective therapy
Autoimmune, personalized medicine, genetic medicine, preclinical - Read more

Avant Genomics raises $3M+ in funding for automated liquid biopsy cancer detection platform
Oncology, liquid biopsy, automation, precision diagnostics - Read more

THE GOOD
Investments

Icon opens early-phase Clinical Research Unit in San Antonio, adds satellite clinics in Houston and Lawrence
CRO services, operational, strategic, infrastructure expansion - Read more

Vetter breaks ground on new Saarlouis production site, investing €500M ($586.75M) to create up to 2,000 jobs
Injectable drugs, CDMO, operational, major transaction - Read more

THE GOOD
Marketing

Galapagos rebrands as Lakefront Biotherapeutics after strategic overhaul, CEO change, and cell therapy exit
Cell therapy, oncology, strategic, rebranding, major transaction - Read more

THE GOOD
Mergers & Acquisitions

Zydus to acquire Assertio Holdings for $23.50 per share, totaling ~$166.4M
Small molecule, specialty pharma, strategic, major transaction - Read more

THE GOOD
Product Launches

Dyno Therapeutics launches two new AAV capsids and AI platform for rare disease gene therapy development at ASGCT
Gene therapy, rare disease, neurological, AI-driven drug discovery - Read more

THE GOOD
Regulatory

MHRA opens Northern Ireland hub to boost life sciences collaboration and regulatory support for region's 250 businesses
Life sciences, regulatory, strategic, operational - Read more

THE GOOD
Strategic Plans

Merck KGaA eyes M&A expansion to strengthen its "rather slim" early-stage pharma pipeline
Small molecule, oncology, strategic, major transaction - Read more

PRESENTED BY YOU?
Get the attention of 3000+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Layoffs

Valneva cuts up to 15% of workforce amid declining travel vaccine demand and geopolitical headwinds
Vaccine, infectious disease, cost reduction, operational - Read more

Medtronic shuts Santa Rosa stent plant, restructures cardiovascular unit amid activist investor pressure
Medical device, cardiovascular, strategic, operational, cost reduction - Read more

Humacyte cuts 25% of workforce, slashes $14.3M in spending amid sluggish Symvess artery implant sales
Bioengineered implant, vascular, cost reduction, operational - Read more

THE BAD
Strategic Plans

Takeda axes TAK-004, marking fourth nausea and vomiting pipeline failure amid strategic shift
Peptide agonist, gastrointestinal, strategic, pipeline - Read more

THE UGLY
Regulatory

Takeda expands restructuring, cutting 4,500 roles to save $1.3B annually by fiscal 2028
Operational, cost reduction, strategic, financial - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

Isomorphic Labs raises $2.1B Series B to develop AI drug design engine, accelerate pipeline | Gif: billions on Giphy

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

Boehringer Ingelheim, Immunitas Therapeutics license preclinical antibody for inflammatory conditions, €407.5M ($478M) milestones
Licensing deal, autoimmune, antibody, milestone payments, royalties - Read more

Arvinas, Pfizer license Veppanu to Rigel Pharmaceuticals for $75M upfront, $320M milestones
Licensing deal, oncology, small molecule, milestone payments, royalties - Read more

Bristol Myers Squibb, Hengrui Pharma build 13-asset oncology and immune disease pipeline in $15.2B deal
Co-development, oncology, autoimmune, small molecule, milestone payments, royalties - Read more

Boehringer Ingelheim, Brainomix expand AI imaging partnership with prospective pulmonary fibrosis study PROGRESS-PPF
Research collaboration, AI/ML, rare disease, diagnostics, small molecule - Read more

CSL Seqirus, PAHO sign multi-year pandemic influenza preparedness agreement for Latin America and Caribbean
Manufacturing agreement, vaccine, infectious disease, pandemic preparedness, supply agreement - Read more

Ribo Life Science, Insilico Medicine partner on AI-driven siRNA therapies and small molecule drug co-development
Co-development, AI/ML, siRNA, small molecule, drug discovery - Read more

PRESENTED BY SCIENCE 2 SALES
Outbound and commercial intelligence built exclusively for selling into biopharma.

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

✅ More Good News ✅

THE GOOD
Clinical Trials

Alkermes' Lumryz (sodium oxybate) meets all Ph3 endpoints in idiopathic hypersomnia, fueling FDA filing plans
Small molecule, neurological, sodium oxybate, idiopathic hypersomnia, narcolepsy, sleep disorder - Read more

Enterprise Therapeutics' ETD001 (ETD001) meets Ph2 primary endpoint, improving lung function in cystic fibrosis patients unresponsive to CFTR modulators
Small molecule, respiratory disease, inhaled therapy, ENaC blocker, cystic fibrosis - Read more

BridgeBio's Attruby (acoramidis) Ph3 data suggest superiority over Pfizer's tafamidis in transthyretin amyloidosis cardiomyopathy
Small molecule, cardiovascular, transthyretin stabilizer, transthyretin amyloidosis cardiomyopathy, TTR protein target - Read more

Alnylam Pharmaceuticals' Amvuttra (vutrisiran) Ph3 data shows consistent TTR-silencing benefit across transthyretin amyloid cardiomyopathy patient populations
RNA interference, cardiovascular, siRNA, transthyretin amyloidosis, cardiomyopathy, TTR silencer - Read more

Eli Lilly's Foundayo (orforglipron) and Zepbound (tirzepatide) Ph3 trials show sustained weight-loss maintenance in obesity
Small molecule, metabolic, GLP-1 receptor agonist, obesity, weight maintenance, incretin therapy - Read more

THE GOOD
Fundraises

Isomorphic Labs raises $2.1B Series B to develop AI drug design engine, accelerate pipeline
AI/ML platform, drug discovery, small molecule, platform-enabled - Read more

Tolemy Bio raises €1.4M ($1.65M) pre-seed to advance AI-driven cell biology platform
Cell biology, AI/ML platform, software platform, drug discovery, virtual cell modeling - Read more

Forus raises $160M to build AI-powered network connecting doctors, pharmacies, and biopharma
AI/ML platform, software platform, data analytics, biopharma services - Read more

Infex Therapeutics secures £4.3M funding to advance anti-infective pipeline targeting drug-resistant infections
Infectious disease, antimicrobial resistance, small molecule, clinical-stage - Read more

CEL-SCI prices $7.2M public offering to advance Multikine cancer immunotherapy development
Oncology, cancer immunotherapy, clinical-stage, immunotherapy - Read more

THE GOOD
Politics & Policy

EU Council and Parliament reach provisional agreement on Critical Medicines Act to combat drug shortages
Small molecule, rare disease, operational, strategic - Read more

THE GOOD
Product Launches

Charles River Laboratories launches AI digital pathology platform, cutting turnaround times by at least one week
AI diagnostics, pathology, operational, strategic - Read more

THE GOOD
Regulatory

FDA launches drug repurposing program targeting metabolic, neurodegenerative, rare diseases, and other unmet medical needs
Drug repurposing, rare disease, metabolic, neurodegenerative - Read more

SMC recommends enfortumab vedotin plus pembrolizumab for metastatic bladder cancer on NHS Scotland
Antibody-drug conjugate, oncology, regulatory, reimbursement - Read more

PRESENTED BY YOU?
Get the attention of 2700+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Clinical Trials

AstraZeneca's (eneboparatide) PTH-1 receptor agonist falls short in Ph3 chronic hypoparathyroidism trial due to immunogenicity
Protein therapy, metabolic, PTH-1 receptor agonist, hypoparathyroidism, immunogenicity - Read more

THE BAD
Earnings & Finances

Bayer's Eylea sales drop 24% amid mounting biosimilar competition in Q1
Monoclonal antibody, ophthalmology, competitive, revenue impact - Read more

THE BAD
Layoffs

BioMarin Pharmaceutical cuts 58 roles at Amicus Therapeutics' Princeton HQ following $4.8B acquisition
Enzyme replacement therapy, rare disease, major transaction, operational, cost reduction - Read more

THE BAD
Strategic Plans

Bayer discontinues Ph1 ANP-based therapy (BAY 2701250) for pulmonary hypertension and diabetic neuropathic pain drug following portfolio review decisions
Protein therapy, cardiovascular, small molecule, hypertension, neuropathic pain, GPR84 antagonist - Read more

THE UGLY
Regulatory

FDA Commissioner Marty Makary resigns after turbulent tenure marked by White House tensions
Regulatory leadership, strategic, operational - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

Inhibrx Biosciences' INBRX-106 plus Keytruda (pembrolizumab) doubles response rate in Ph2 head and neck squamous cell carcinoma trial | Gif: iitsad on Giphy

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

GSK, Sino Biopharmaceutical partner to distribute hepatitis B drug bepirovirsen across China
Commercialization agreement, infectious disease, small molecule, RNA-based therapy - Read more

MacroGenics sells GMP manufacturing operations to Bora Pharmaceuticals for $122.5M upfront
Acquisition, manufacturing, biologics, antibody, oncology, CDMO - Read more

Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy STEM-PD, equity investment undisclosed
Acquisition, neurological, cell therapy, AI/ML, milestone payments, royalties - Read more

Nxera Pharma out-licenses GPCR program to NewCo, eligible for up to $275M in milestones plus royalties
Licensing deal, small molecule, drug discovery, milestone payments, equity investment, rare disease - Read more

Curacle, MabTics, Memento Medicines sign $1.08B dual-antibody MT-103 technology transfer deal, $8M upfront
Licensing deal, antibody, milestone payments, royalties - Read more

PRESENTED BY SCIENCE 2 SALES
Outbound and commercial intelligence built exclusively for selling into biopharma.

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

✅ More Good News ✅

THE GOOD
Clinical Trials

Inhibrx Biosciences' INBRX-106 plus Keytruda (pembrolizumab) doubles response rate in Ph2 head and neck squamous cell carcinoma trial
Antibody, cancer, monoclonal antibody, head and neck squamous cell carcinoma, OX40 agonist, combination therapy - Read more

PulseSight Therapeutics' PST-611 shows positive Ph1 safety and efficacy signals in dry age-related macular degeneration
Gene therapy, neurological, non-viral gene therapy, age-related macular degeneration, geographic atrophy - Read more

Braveheart Bio and Hengrui Pharma's (BHB-1893) cardiac myosin inhibitor shows Ph2 promise in non-obstructive hypertrophic cardiomyopathy
Small molecule, cardiovascular, cardiac myosin inhibitor, hypertrophic cardiomyopathy, non-obstructive HCM - Read more

THE GOOD
Company Incubation

Delos Capital, AP Biosciences collaborate to incubate next-generation antibody-focused biotech companies
Co-development, antibody, autoimmune, venture building, R&D - Read more

THE GOOD
Earnings & Finances

Daiichi Sankyo targets $14.6B oncology sales by 2030, aiming for global top-five cancer company status
Antibody-drug conjugate, oncology, strategic, financial - Read more

THE GOOD
Fundraises

Scarlet Therapeutics raises £3.2M ($4.35M) to advance engineered red blood cell therapies for metabolic diseases
Cell therapy, rare disease, metabolic disease, platform technology, preclinical - Read more

Algorithmiq raises €18M ($21.18M) in funding for quantum computing drug discovery expansion
Quantum computing, drug discovery, molecular simulation, software platform - Read more

THE GOOD
Regulatory

Poolbeg Pharma secures Canadian patent for POLB 001 targeting cancer immunotherapy-induced cytokine release syndrome
Small molecule, oncology, intellectual property, strategic - Read more

PRESENTED BY YOU?
Get the attention of 2700+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Earnings & Finances

CSL slashes revenue forecast by $600M, takes $5B impairment amid R&D failures and market erosion
Plasma-derived therapy, rare disease, financial, operational, strategic - Read more

Daiichi Sankyo takes $850M charge, scraps facility investment amid falling ADC demand forecast
Antibody-drug conjugate, oncology, financial, operational, cost reduction - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

Quantinuum plans IPO to fund quantum computing platform for drug discovery | Gif: blockfi on Giphy

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Partner Therapeutics' Bizengri (zenocutuzumab-zbco) gains FDA label expansion for NRG1 fusion-positive cholangiocarcinoma based on Ph1/Ph2 data
Antibody, cancer, bispecific antibody, cholangiocarcinoma, NRG1 fusion, HER2/HER3 target - Read more

argenx's VYVGART (efgartigimod alfa-fcab) receives FDA label expansion for all adult generalized myasthenia gravis serotypes
Protein therapy, autoimmune, monoclonal antibody, generalized myasthenia gravis, FcRn antagonist, efgartigimod - Read more

Genentech's Ocrevus (ocrelizumab) receives FDA approval for pediatric relapsing-remitting multiple sclerosis in patients aged 10 and older
Antibody, autoimmune, monoclonal antibody, multiple sclerosis, pediatric patients, CD20 target - Read more

Knight Therapeutics' TAVALISSE (fostamatinib) receives Brazil ANVISA approval for chronic immune thrombocytopenia in adults
Small molecule, autoimmune, SYK inhibitor, immune thrombocytopenia - Read more

NICE recommends Johnson & Johnson's RYBREVANT plus chemotherapy for EGFR exon 20 NSCLC via Cancer Drugs Fund
Monoclonal antibody, oncology, regulatory, managed access - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

✅ More Good News ✅

THE GOOD
Business Development & Partnerships

LenioBio, Twist Bioscience partner to accelerate AI-designed protein wet-lab validation using ALiCE platform
Research collaboration, AI/ML, drug discovery, antibody, cell-free expression - Read more

THE GOOD
Clinical Trials

Raynovent Biotech's ZSP1601 meets primary endpoint in Ph2b trial for metabolic dysfunction-associated steatohepatitis
Small molecule, metabolic, pan-PDE inhibitor, MASH, liver fibrosis - Read more

THE GOOD
Earnings & Finances

Gilead raises Yeztugo 2026 sales target to $1B after strong launch trajectory
Small molecule, infectious disease, revenue impact, CAR-T, oncology - Read more

Gilead raises 2026 sales outlook after strong HIV growth, despite expected earnings hit from $11.5B acquisition spending
Cell therapy, oncology, major transaction, financial, strategic - Read more

THE GOOD
Fundraises

Artiva Biotherapeutics prices $300M offering of common stock and pre-funded warrants, autoimmune cell therapies
Cell therapy, autoimmune, clinical-stage - Read more

THE GOOD
IPOs

Quantinuum plans IPO to fund quantum computing platform for drug discovery
Quantum computing, AI/ML platform, drug discovery, platform technology - Read more

PRESENTED BY YOU?
Get the attention of 2700+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Earnings & Finances

Daiichi Sankyo takes $610M profit hit from ADC manufacturing overcapacity amid shifting demand forecasts
Antibody-drug conjugate, oncology, operational, financial, cost reduction - Read more

THE BAD
Lawsuits

Capricor Therapeutics sues US partner NS Pharma for breach of contract over deramiocel launch failures
Cell therapy, rare disease, operational, financial - Read more

THE BAD
Regulatory

Biogen, Eisai face 3-month FDA delay for subcutaneous Leqembi (lecanemab) initiation in Alzheimer's disease
Antibody, neurological, monoclonal antibody, Alzheimer's disease, amyloid, subcutaneous delivery - Read more

THE UGLY
Politics & Policy

Trump expected to remove FDA Commissioner Marty Makary amid leadership turmoil, reports say
Leadership change, regulatory, operational, strategic - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1B, expanding into U.S. rare neurological drug market | Gif: CompanyCam on Giphy

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

UCB, Cancer Research UK expand strategic alliance to advance novel oncology therapies with milestone and royalty payments
Research collaboration, oncology, antibody, milestone payments, royalties, co-development - Read more

AstraZeneca, Immunai expand AI oncology pact through 2027, up to $37.5M deal
Research collaboration, oncology, AI/ML, milestone payments, drug discovery - Read more

Halozyme Therapeutics, GSK collaborate on subcutaneous oncology ADC formulations using ENHANZE technology
Licensing deal, oncology, antibody drug conjugates, drug delivery, milestone payments, royalties - Read more

Bristol Myers Squibb licenses Lonza's SYNtecan ADC linker-payload platform for undisclosed target, milestones and royalties eligible
Licensing deal, antibody-drug conjugate, drug discovery, milestone payments, royalties - Read more

THE GOOD
Clinical Trials

Avalo Therapeutics' (abdakibart) meets Ph2 primary endpoint in moderate-to-severe hidradenitis suppurativa, advancing toward registrational study
Antibody, autoimmune, monoclonal antibody, hidradenitis suppurativa, IL-1β, skin disease - Read more

AIM ImmunoTech's Ampligen (rintatolimod) achieves 50% objective response rate in Ph2 recurrent ovarian cancer trial
Small molecule, cancer, combination therapy, ovarian cancer, checkpoint inhibitor, immunotherapy - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

✅ More Good News ✅

THE GOOD
Company Launches

Banyan BioInnovations launches with $100M and Icon partnership to develop clinical-stage NewCo companies
Co-development, clinical-stage, CRO partnership, equity investment, R&D, commercialization - Read more

THE GOOD
Fundraises

Blackstone invests $250M in Anagram Therapeutics to develop cystic fibrosis EPI therapy
Cystic fibrosis, rare disease, enzyme replacement therapy, oral therapy, clinical-stage - Read more

Viridian Therapeutics raises $350M via convertible notes and equity offerings for autoimmune and rare diseases
Autoimmune, rare disease, clinical-stage, small molecule - Read more

ParcelBio raises $13M seed round to advance APEXm mRNA expression platform
mRNA platform, Cell therapy, Autoimmune, Oncology, Preclinical, Platform technology - Read more

Odyssey Therapeutics prices upsized $304M IPO for autoimmune and inflammatory disease medicines
Autoimmune, inflammatory disease, clinical-stage, small molecule - Read more

Cartography Biosciences receives undisclosed Samsung Ventures investment for oncology pipeline advancement
Oncology, antibody, AI-driven, drug discovery, clinical-stage - Read more

Cytokinetics prices upsized $700M public offering of common stock
Cardiovascular, small molecule, clinical-stage - Read more

THE GOOD
Mergers & Acquisitions

Roche to acquire PathAI for up to $1.05B to expand digital pathology and AI diagnostics globally
Digital pathology, oncology, major transaction, strategic - Read more

Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1B, expanding into U.S. rare neurological drug market
Small molecule, rare disease, neurological, major transaction, strategic - Read more

THE GOOD
Regulatory

Pierre Fabre, FDA align on Ebvallo BLA resubmission path using updated ALLELE study data
Allogeneic T-cell therapy, rare disease, regulatory, strategic - Read more

PRESENTED BY YOU?
Get the attention of 2700+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Clinical Trials

BeOne Medicines halts Ph2 trial of (BGB-45035), IRAK4 degrader, in rheumatoid arthritis amid emerging new data
Small molecule, cancer, autoimmune, EGFR inhibitor, KRAS inhibitor, CDK2 inhibitor - Read more

Entrada Therapeutics' (ENTR-601-44) Ph1/2 dystrophin data falls below expectations in Duchenne muscular dystrophy trial
Oligonucleotide, neurological, antisense oligonucleotide, Duchenne muscular dystrophy, exon skipping, dystrophin - Read more

enGene Therapeutics' (detalimogene voraplasmid) Ph2 data disappoints in BCG-unresponsive non-muscle-invasive bladder cancer with waning durability
Gene therapy, cancer, bladder cancer, non-muscle-invasive bladder cancer, BCG-unresponsive, intravesical delivery - Read more

THE BAD
Earnings & Finances

Sarepta Therapeutics shares tumble 10% as Elevidys gene therapy sales continue quarterly decline
Gene therapy, rare disease, financial, competitive, siRNA - Read more

THE BAD
Regulatory

FDA rebukes Alnylam over misleading Amvuttra website efficacy claims using open-label data
RNAi therapy, cardiovascular, regulatory, competitive - Read more

THE BAD
Strategic Plans

Ascendis Pharma axes IL-2 cancer program, refocusing pipeline on rare endocrinology diseases
IL-2 cytokine, oncology, strategic, pipeline discontinuation - Read more

THE UGLY
Layoffs

Gilead wipes out 87% of Arcellx workforce, laying off 192 employees after $7.8B acquisition
CAR-T, multiple myeloma, major transaction, cost reduction - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

Eli Lilly pledges additional $4.5B to Indiana campus, expanding genetic medicine and metabolic disease manufacturing. | Gif: Disney

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

GSK, SiranBio partner on oligonucleotide SA030 for cardiometabolic disease, $55M upfront, $1B milestones
Licensing deal, oligonucleotide, cardiometabolic, obesity, milestone payments, royalties - Read more

THE GOOD
Clinical Trials

J&J MedTech's Ottava surgical robot meets primary endpoints in Ph1 gastric bypass clinical study
Medical device, metabolic, surgical robotics, obesity, bariatric surgery - Read more

MingMed Biotechnology's QA102 shows positive Ph2 results slowing intermediate dry age-related macular degeneration progression
Small molecule, ophthalmology, age-related macular degeneration, oral therapy, drusen volume, dry AMD - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

✅ More Good News ✅

THE GOOD
Earnings & Finances

Novo Nordisk's Wegovy pill hits 1M patients, generates $355M in Q1 sales, beating analyst expectations by 86%
Small molecule, metabolic disease, revenue impact, competitive - Read more

THE GOOD
Fundraises

CellCentric raises $220M Series D to advance inobrodib for multiple myeloma
Oncology, small molecule, multiple myeloma, clinical-stage - Read more

Signadori Bio raises €11M ($12.9M) Seed round to advance solid tumour monocyte immunotherapy platform
Oncology, cell therapy, immuno-oncology, preclinical, solid tumors, platform technology - Read more

Avalo Therapeutics prices $375M public offering to advance abdakibart clinical development
Clinical-stage, autoimmune, antibody, IL-1β, inflammatory disease - Read more

Citius Oncology secures up to $36.5M in debt and equity to accelerate LYMPHIR commercialization
Oncology, small molecule, cutaneous T-cell lymphoma, clinical-stage - Read more

Kanvas Biosciences raises $48M Series A to advance gut microbiome immuno-oncology candidate
Oncology, microbiome, live biotherapeutic, immuno-oncology, AI/ML platform, preclinical - Read more

Brano Therapeutics raises $6.8M seed funding to advance heart failure treatments
Cardiovascular, small molecule, heart failure, preclinical - Read more

LTZ Therapeutics raises $38M to advance myeloid engager immunotherapy pipeline
Clinical-stage, oncology, autoimmune, immunotherapy, platform technology - Read more

THE GOOD
Investments

Eli Lilly pledges additional $4.5B to Indiana campus, expanding genetic medicine and metabolic disease manufacturing
Gene therapy, metabolic disease, major transaction, operational - Read more

THE GOOD
Mergers & Acquisitions

Bayer to acquire Perfuse Therapeutics for up to $2.45B, bolstering eye disease drug pipeline
Small molecule, ophthalmology, major transaction, strategic - Read more

THE GOOD
Regulatory

FDA launches AI-guided one-day inspection pilot to boost facility oversight efficiency
Manufacturing, operational, strategic, compliance - Read more

PRESENTED BY YOU?
Get the attention of 2700+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Clinical Trials

Ipsen discontinues (ritivixibat) Ph2 trial in primary sclerosing cholangitis due to recruitment challenges
Small molecule, liver disease, IBAT inhibitor, primary sclerosing cholangitis, bile acid transporter - Read more

THE BAD
Politics & Policy

Bipartisan PRIMATE Act introduced to ban monkey imports for US research labs
Preclinical research, biosecurity, operational, regulatory - Read more

THE BAD
Regulatory

Novo Nordisk, Eli Lilly fined by French regulator for illegal indirect obesity drug promotion campaigns
GLP-1, obesity, regulatory, financial - Read more

FDA blocks publication of COVID and GSK Shingrix vaccine safety studies, citing unsupported conclusions
mRNA vaccine, infectious disease, regulatory, operational - Read more

THE BAD
Strategic Plans

BioCryst Pharmaceuticals scraps avoralstat eye candidate to refocus pipeline on rare diseases
Small molecule, rare disease, strategic, pipeline prioritization - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

Pfizer beats Q1 earnings with $14.5B revenue, maintains 2026 guidance despite COVID portfolio decline | Gif: bombaysoftwares on Giphy

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

Olympus, EndoRobotics partner on global distribution of robot-assisted endoscopic technologies
Distribution agreement, robotics, endoscopy, commercialization - Read more

Madrigal Pharmaceuticals, Arrowhead Pharmaceuticals license ARO-PNPLA3 for MASH, $25M upfront, up to $1B total
Licensing deal, MASH/liver disease, siRNA/RNAi, milestone payments - Read more

THE GOOD
Clinical Trials

Cytokinetics' Myqorzo meets dual Ph3 endpoints in non-obstructive hypertrophic cardiomyopathy trial
Small molecule, cardiovascular, cardiac myosin inhibitor, hypertrophic cardiomyopathy, non-obstructive HCM - Read more

Viridian Therapeutics' (elegrobart) IGF-1R blocker succeeds in Ph3 trial for chronic thyroid eye disease
Antibody, autoimmune, monoclonal antibody, thyroid eye disease, IGF-1R, subcutaneous injection - Read more

Palisade Bio's PALI-2108 (pali-2108) Ph1 data show colon-targeted PDE4 inhibition in ulcerative colitis
Small molecule, autoimmune, PDE4 inhibitor, ulcerative colitis, inflammatory bowel disease - Read more

QurAlis' QRL-201 (stathmin-2 ASO) shows 50% disease progression reduction in Ph2 amyotrophic lateral sclerosis trial
Antisense oligonucleotide, neurological, ALS, STMN2 target, genetic medicine - Read more

Johnson & Johnson's JNJ-4804 (golimumab/guselkumab) advances to Ph3 for ulcerative colitis and Crohn's disease after Ph2 DUET data
Antibody, autoimmune, monoclonal antibody, combination therapy, inflammatory bowel disease, TNF/IL-23 inhibitor - Read more

Hepta's cfDNA methylation assay predicts GLP-1 (semaglutide) response before treatment in metabolic dysfunction-associated steatotic liver disease
Small molecule, metabolic, GLP-1 agonist, MASH, liquid biopsy, precision medicine - Read more

Avalo Therapeutics' (abdakibart) meets primary endpoint in Ph2 trial for moderate to severe hidradenitis suppurativa
Antibody, autoimmune, monoclonal antibody, hidradenitis suppurativa, IL-1β inhibition - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

✅ More Good News ✅

THE GOOD
Earnings & Finances

Axsome Therapeutics raises Auvelity peak sales projection to $8B after FDA Alzheimer's agitation approval
Small molecule, neurological, revenue impact, competitive - Read more

Vertex Pharmaceuticals' steady Q1 precedes potential 'iconic' renal portfolio evolution led by povetacicept
Fusion protein, renal disease, rare disease, financial - Read more

Pfizer beats Q1 earnings with $14.5B revenue, maintains 2026 guidance despite COVID portfolio decline
Small molecule, oncology, cardiovascular, financial - Read more

THE GOOD
Fundraises

Cytospire raises $83M to develop gamma delta T cell engagers for solid tumors
Oncology, antibody, T cell engager, solid tumors, preclinical - Read more

Dandelion Health raises $14M Series A to advance multimodal clinical AI platform for pharma
AI/ML platform, data analytics, biomarker discovery, clinical trial platform, real-world evidence - Read more

THE GOOD
Investments

Sanofi invests $294M to expand Toronto AI center, targeting drug discovery and manufacturing acceleration
AI/machine learning, drug discovery, strategic, operational - Read more

THE GOOD
Market Reports

Swiss private biotech funding surges 38% to record $1.5B in 2025, marking third straight year of growth
Autoimmune, oncology, rare disease, clinical-stage, small molecule, antibody - Read more

PRESENTED BY YOU?
Get the attention of 2700+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Layoffs

Gilead trims 108 jobs at Arcellx's Redwood City site following $7.8B acquisition close
CAR-T, oncology, major transaction, operational - Read more

Novartis to close German manufacturing site in Wehr by 2028, eliminating 220 jobs
Radioligand therapy, oncology, operational, cost reduction - Read more

BioNTech closes four manufacturing plants, cutting 1,860 jobs to save €500M ($585M) annually by 2029
mRNA vaccine, oncology, cost reduction, operational - Read more

THE BAD
Regulatory

Amarox recalls sertraline batch after citalopram blister strip found mixed in UK packaging
Small molecule, neurological, operational, safety recall - Read more

THE BAD
Strategic Plans

Pfizer drops (maplirpacept) from pipeline, ending CD47 blocker program for blood cancers after Ph1/Ph2 studies
Antibody, cancer, CD47 inhibitor, blood cancer, B-cell lymphoma - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

Amgen adds $300M to Puerto Rico biologics expansion, bringing total U.S. investment pledges near $2B | Gif: pudgypenguins on Giphy

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Specialised Therapeutics' NIKTIMVO (axatilimab) gains Australian TGA approval for chronic graft-versus-host disease based on Ph2 data
Antibody, autoimmune, monoclonal antibody, chronic graft-versus-host disease, CSF-1R inhibitor, stem cell transplant - Read more

FDA approves Guardant Health’s Guardant360 CDx as companion diagnostic for Arvinas and Pfizer's Veppanu (vepdegestrant) in ESR1-mutated advanced breast cancer
Small molecule, cancer, PROTAC, breast cancer, ESR1 mutation, companion diagnostic - Read more

THE GOOD
Business Development & Partnerships

Novelty Nobility, AGC Biologics expand manufacturing partnership to advance bispecific antibody NN4101 for retinal diseases
Manufacturing agreement, Bispecific antibody, Ophthalmology, CDMO, GMP manufacturing - Read more

BioCryst Pharmaceuticals, Neopharmed Gentili license navenibart in Europe for HAE, $70M upfront, $275M milestones
Licensing deal, rare disease, small molecule, milestone payments, royalties, commercialization - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

✅ More Good News ✅

THE GOOD
Clinical Trials

Takeda's TAK-881 (immunoglobulin 20%) meets Ph2/3 primary endpoint in primary immunodeficiency disease, showing pharmacokinetic comparability to HyQvia
Protein therapy, autoimmune, immunoglobulin, primary immunodeficiency disease, subcutaneous therapy - Read more

Mirum Pharmaceuticals' (volixibat) meets primary endpoint in Ph2b trial for primary sclerosing cholangitis-related pruritus
Small molecule, liver disease, IBAT inhibitor, primary sclerosing cholangitis, cholestatic pruritus - Read more

Lineage Cell Therapeutics' OpRegen (RG6501) Ph1/2a shows durable 3-year vision gains in geographic atrophy secondary to age-related macular degeneration
Cell therapy, eye disease, allogeneic cell therapy, geographic atrophy, age-related macular degeneration, retinal pigment epithelium - Read more

Dr. Falk Pharma and Renexxion's naronapride meets primary endpoint in Ph2b gastroparesis trial
Small molecule, metabolic, gastroparesis, prokinetic, 5-HT4 receptor agonist - Read more

Spur Therapeutics' (avigbagene parvec) Ph1/Ph2 data show bone disease improvements in Gaucher disease type 1 adults
Gene therapy, metabolic, AAV gene therapy, Gaucher disease, GCase, rare disease - Read more

Oncolytics Biotech's (pelareorep) Ph2 shows durable responses in second-line RAS-mutant microsatellite-stable metastatic colorectal cancer
Oncolytic virus, cancer, immunotherapy, colorectal cancer, RAS mutation, combination therapy - Read more

THE GOOD
Fundraises

Windward Bio raises $165M crossover round, advancing TSLP-targeting immunology antibody programmes
Immunology, antibody, respiratory, dermatology, clinical-stage - Read more

Odyssey Therapeutics targets $225M IPO to advance inflammatory disease pipeline
Autoimmune, small molecule, inflammatory disease, clinical-stage, protein therapeutics - Read more

Latus Bio raises $97M Series A to advance gene therapies for Huntington's, Batten disease
Gene therapy, neurological, rare disease, Huntington's disease, clinical-stage - Read more

mbiomics raises $12M Series A, advancing microbiome-based therapeutics for severe diseases
Microbiome therapeutics, AI/ML platform, infectious disease, preclinical, live biotherapeutics - Read more

General Proximity receives undisclosed investment to expand induced proximity medicines development
Oncology, induced proximity, small molecule, platform technology, preclinical - Read more

EnteroBiotix raises £19M (25.8M), advancing microbiome therapies for gut health R&D
Microbiome therapeutics, gastrointestinal, clinical-stage, oral therapy - Read more

THE GOOD
Investments

Amgen adds $300M to Puerto Rico biologics expansion, bringing total U.S. investment pledges near $2B
Biologics, strategic, operational, major transaction - Read more

PCI Pharma Services adds US sterile fill/finish capabilities amid $1B global expansion
Sterile fill/finish, CDMO expansion, strategic, major transaction - Read more

THE GOOD
Market Reports

Obesity surpasses oncology as top biopharma pipeline value contributor for first time, per Deloitte analysis
GLP-1 receptor agonist, obesity, competitive, financial - Read more

THE GOOD
Politics & Policy

SCOTUS temporarily restores online mifepristone access after appeals court blocked Danco, GenBioPro distribution
Small molecule, reproductive health, regulatory, operational - Read more

PRESENTED BY YOU?
Get the attention of 2700+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Clinical Trials

Vertex Pharmaceuticals, Moderna discontinue (VX-522) Ph1/Ph2 cystic fibrosis program due to tolerability issues with CFTR mRNA therapy
Gene therapy, respiratory disease, mRNA therapy, cystic fibrosis, CFTR protein - Read more

THE BAD
Earnings & Finances

Samsung Biologics estimates $102M financial impact as union strike involving 2,800+ workers continues
CDMO, operational, financial, labor dispute - Read more

THE BAD
Layoffs

Novartis cuts 60 more US headquarters roles in second layoff round at East Hanover site
Rare disease, oncology, cost reduction, operational - Read more

Passage Bio cuts 75% of workforce after FDA rejects single-arm trial design for PBFT02
Gene therapy, neurological, cost reduction, strategic - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

Arvinas' Veppanu (vepdegestrant) receives first-ever FDA approval for estrogen receptor-positive, HER2-negative metastatic breast cancer with ESR1 mutations | Gif: CMNHospitals on Giphy

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Arvinas' Veppanu (vepdegestrant) receives first-ever FDA approval for estrogen receptor-positive, HER2-negative metastatic breast cancer with ESR1 mutations
Small molecule, cancer, PROTAC, breast cancer, ESR1 mutation, estrogen receptor degrader - Read more

THE GOOD
Business Development & Partnerships

UCB acquires IMIDomics' patient insights business to advance precision medicine in inflammatory diseases
Acquisition, autoimmune, data analytics, precision medicine, multi-omics - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

✅ More Good News ✅

THE GOOD
Clinical Trials

Corcept Therapeutics' dazucorilant linked to 87% death risk reduction in Ph2 amyotrophic lateral sclerosis study ahead of Ph3
Small molecule, neurological, cortisol modulator, ALS, survival benefit - Read more

Everads Therapy publishes Ph1 first-in-human data for Everads Injector in diabetic macular edema
Small molecule, ophthalmology, drug delivery, diabetic macular edema, suprachoroidal injection, triamcinolone acetonide - Read more

Restore Vision's RV-001 shows Ph1/2 interim vision gains in advanced retinitis pigmentosa patients via GPCR optogenetic gene therapy
Gene therapy, neurological, AAV vector, optogenetics, retinitis pigmentosa, GPCR - Read more

Celcuity's (gedatolisib) Ph3 trial meets primary endpoint in PIK3CA mutant hormone receptor-positive, HER2-negative advanced breast cancer
Small molecule, cancer, PI3K/AKT/mTOR pathway, breast cancer, PIK3CA mutation, combination therapy - Read more

THE GOOD
Earnings & Finances

Moderna Q1 revenue triples to $389M, driven by international COVID-19 vaccine sales
mRNA vaccine, infectious disease, financial, revenue impact - Read more

Amgen Q1 revenue rises 6% to $8.6B as Repatha's 34% sales surge offsets Prolia biosimilar losses
Monoclonal antibody, cardiovascular, revenue impact, competitive - Read more

THE GOOD
Fundraises

Hemab Therapeutics prices upsized $301.5M IPO, developing blood coagulation disorder therapies
Hematology, blood coagulation, clinical-stage, rare disease - Read more

Seaport Therapeutics prices upsized $254.9M IPO for neuropsychiatric medicine development
Neuropsychiatric, clinical-stage, small molecule - Read more

Stoked Bio closes Seed round, advancing anti-infectives and cancer therapeutics pipeline
Anti-infectives, oncology, AI-driven, small molecule, neurological, infectious disease - Read more

THE GOOD
Marketing

Novo Nordisk retires Rybelsus brand, rebrands oral semaglutide tablet as "Ozempic pill" in US
Small molecule, type 2 diabetes, strategic, competitive, brand marketing - Read more

THE GOOD
Mergers & Acquisitions

Esperion to go private in $1.1B deal with investment firm ARCHIMED, shareholders receive 58% premium
Small molecule, cardiovascular, strategic, major transaction - Read more

UCB to acquire Candid Therapeutics for $2.2B, expanding T-cell engager pipeline for autoimmune diseases
T-cell engager, autoimmune, strategic, major transaction - Read more

THE GOOD
Regulatory

FDA names Katherine Szarama as acting CBER director following Vinay Prasad's departure
Gene therapy, rare disease, regulatory, operational - Read more

PRESENTED BY YOU?
Get the attention of 2700+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Business Development & Partnerships

Ligand Pharmaceuticals terminates TRβ program licenses with Viking Therapeutics, alleging contract breach
Licensing deal, small molecule, metabolic disease, royalties, contract dispute - Read more

THE BAD
Clinical Trials

Amgen drops (adezkibart) for Sjögren's syndrome, (anvumetostat) for cancer after Ph2 futility failures
Small molecule, antibody, cancer, autoimmune, Sjögren's syndrome, lung cancer - Read more

Summit Therapeutics' ivonescimab (ivonescimab) Ph3 interim progression-free survival analysis misses bar in squamous non-small-cell lung cancer
Small molecule, cancer, antibody, non-small cell lung cancer, PD-1/VEGF bispecific, combination therapy - Read more

Bristol Myers Squibb's Krazati (adagrasib) faces colorectal cancer approval setback after Ph3 KRAS inhibitor trial failure
Small molecule, cancer, KRAS inhibitor, colorectal cancer, non-small cell lung cancer - Read more

THE BAD
Strategic Plans

J&J discontinues Ph1 JNJ-4496 (dual CD19/CD20 CAR-T) and JNJ-9530 programs for large B-cell lymphoma
Cell therapy, cancer, CAR-T, non-Hodgkin lymphoma, CD19, CD20 - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

Axsome Therapeutics' Auvelity (dextromethorphan/bupropion) receives FDA approval for agitation associated with Alzheimer's disease dementia. | Gif: KungFuPanda4 on Giphy

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Curocell's RIMQARTO (anbalcabtagene autoleucel) wins full South Korea approval for relapsed or refractory diffuse large B-cell lymphoma following Ph2 success
Cell therapy, cancer, CAR-T, diffuse large B-cell lymphoma, CD19, autologous T-cell therapy - Read more

Axsome Therapeutics' Auvelity (dextromethorphan/bupropion) receives FDA approval for agitation associated with Alzheimer's disease dementia
Small molecule, neurological, combination therapy, Alzheimer's disease, NMDA receptor antagonist, agitation - Read more

THE GOOD
Business Development & Partnerships

BeOne Medicines, Huahui Health strike $2B option deal for preclinical trispecific antibody HH160
Licensing deal, oncology, antibody, milestone payments, royalties - Read more

AstraZeneca licenses preclinical EGFR degrader from Pinetree Therapeutics for $25M, up to $500M milestones
Licensing deal, oncology, targeted protein degradation, small molecule, milestone payments, royalties - Read more

Formosa Pharmaceuticals, Singapore Eye Research Institute partner to advance ophthalmic formulations for corneal diseases
Research collaboration, Ophthalmology, Drug delivery, Small molecule, R&D - Read more

Guardant Health, Nuvalent collaborate on companion diagnostics for targeted cancer therapies
Research collaboration, Oncology, Diagnostics, Small molecule, Companion diagnostics - Read more

Cue Biopharma, Ascendant Health Sciences license anti-IgE antibody Ascendant-221, $15M upfront, $676.5M milestones
Licensing deal, autoimmune, antibody, milestone payments, royalties - Read more

PRESENTED BY NUCLEATE
Apply for the 2026 Lilly Grand Challenge: Aging Reimagined

🚨 Applications are open for the 2026 Lilly Grand Challenge: Aging Reimagined

🔬 $100K in non-dilutive funding (no strings attached)
🏛️ A 2 day pitch at Lilly HQ in Indianapolis (all expenses paid)
🤝 Direct access to Lilly's scientific and venture teams

This year’s focus: Aging Reimagined — New Health Frontiers (mobility, cognition, immune resilience, regenerative medicine).

If you’re building in this space - or know someone who is - don’t miss this!

📅 Deadline: May 15

👉 Learn More and Apply Here: https://linktr.ee/lillygrandchallenge

✅ More Good News ✅

THE GOOD
Clinical Trials

Contineum Therapeutics' (PIPE-791) LPA1 antagonist shows positive Ph1b results in chronic osteoarthritis and low back pain
Small molecule, pain, LPA1 receptor antagonist, chronic pain, osteoarthritis - Read more

THE GOOD
Earnings & Finances

Merck & Co.'s Keytruda hits $8B in Q1 2025, with SC formulation Qlex gaining momentum
Monoclonal antibody, oncology, financial, strategic - Read more

Bristol Myers Squibb beats Q1 forecasts with Eliquis sales climbing 16% to $4.1B despite pricing headwinds
Small molecule, cardiovascular, revenue impact, competitive - Read more

Eli Lilly beats Q1 expectations with $19.8B revenue, raises full-year guidance
GLP-1 agonist, diabetes, financial, revenue impact - Read more

Alnylam Pharmaceuticals surpasses expectations as Amvuttra sales surge 187% to $889.9M in Q1
RNAi therapy, rare disease, revenue impact, financial - Read more

THE GOOD
Fundraises

Myomaker Bio raises £325K ($443K) seed funding from SFC Capital for lab-grown human muscle platform
Bioengineered tissue, preclinical, drug discovery, platform technology - Read more

Valneva raises €84M ($98M) reserved offering to advance vaccine pipeline and commercial growth
Vaccines, infectious disease, clinical-stage - Read more

Ascendo Biotechnology closes Series A funding to advance innate immune checkpoint therapies
Innate immunity, oncology, antibody, clinical-stage - Read more

Iterative Health closes $77M Series C to expand clinical research network into new therapeutic areas
Clinical trial platform, CRO, AI-driven, gastroenterology - Read more

Moleculent raises $20M in funding, mapping cell-cell communication in human tissue
Spatial biology, platform technology, cell-cell communication, biomarker discovery - Read more

THE GOOD
Investments

Novartis finalizes $23B US expansion with seventh facility, an API plant in North Carolina
Small molecule, RNA therapeutics, strategic, operational, manufacturing expansion - Read more

THE GOOD
Mergers & Acquisitions

CareDx acquires Naveris for up to $260M, entering oncology with HPV cancer liquid biopsy platform
Liquid biopsy, oncology, strategic, major transaction - Read more

Leo Pharma acquires Replay for $50M, gaining preclinical HSV gene therapy platform for rare skin diseases
Gene therapy, rare disease, strategic, major transaction - Read more

THE GOOD
Regulatory

EMA launches advisory group to combat growing vaccine hesitancy across Europe
Vaccine, infectious disease, strategic, operational - Read more

THE GOOD
Strategic Plans

UniQure to seek UK approval for Huntington's gene therapy AMT-130, shares surge 20%
Gene therapy, neurological, regulatory, strategic - Read more

PRESENTED BY YOU?
Get the attention of 2700+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Approvals & Labels

AstraZeneca's (camizestrant) faces FDA panel rejection for estrogen receptor-mutated hormone receptor-positive, HER2-negative metastatic breast cancer in Ph3
Small molecule, cancer, oral SERD, breast cancer, ESR1 mutation, CDK4/6 inhibitor - Read more

THE BAD
Business Development

Bristol Myers Squibb ends Zymeworks bispecific cancer collaboration, forgoing $313M in potential milestones
Partnership termination, Oncology, Bispecific antibody, Milestone payments, Solid tumors - Read more

THE BAD
Clinical Trials

Indivior's INDV-2000 (orexin-1 receptor antagonist) fails Ph2 primary endpoint for opioid use disorder treatment
Small molecule, neurological, orexin-1 receptor antagonist, opioid use disorder, buprenorphine - Read more

GSK, Alector's (nivisnebart) Ph2 trial halted in early Alzheimer's disease due to futility
Antibody, neurological, monoclonal antibody, Alzheimer's disease, frontotemporal dementia - Read more

THE BAD
Regulatory

FDA issues untitled letter to Bayer over misleading Nubeqa ads with distracting visuals
Small molecule, oncology, regulatory, operational - Read more

Amarox recalls UK batch of sertraline tablets after packaging mix-up includes wrong antidepressant
Small molecule, neurological, operational, safety - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

GSK's Shingrix strategy shift targeting comorbid patients drives $1.4B Q1 sales, beating analyst forecasts.

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Dr. Reddy's generic semaglutide approved in Canada, marking G7-first challenge to Novo Nordisk's Ozempic
Small molecule, diabetes, competitive, revenue impact - Read more

THE GOOD
Business Development & Partnerships

BioDuro, CTI Biotechnology partner to build integrated preclinical drug development platform targeting IND submission
Research collaboration, drug discovery, preclinical development, R&D, manufacturing - Read more

Kahimmune Therapeutics, Gustave Roussy collaborate on mRNA neoantigen therapy KAH-001, backed by €190,000 ($222K) funding
Research collaboration, oncology, mRNA therapy, drug discovery, neoantigen immunotherapy - Read more

Greywolf Therapeutics, Genomics partner to develop first-in-class autoimmune disease treatments targeting ERAP variants
Research collaboration, autoimmune, drug discovery, genetic data analytics, small molecule - Read more

OSR Holdings, BCM Europe sign $815M global license agreement for oral immunotherapy VXM01
Licensing deal, oncology, vaccine, milestone payments, royalties - Read more

PRESENTED BY NUCLEATE
Apply for the 2026 Lilly Grand Challenge: Aging Reimagined

🚨 Applications are open for the 2026 Lilly Grand Challenge: Aging Reimagined

🔬 $100K in non-dilutive funding (no strings attached)
🏛️ A 2 day pitch at Lilly HQ in Indianapolis (all expenses paid)
🤝 Direct access to Lilly's scientific and venture teams

This year’s focus: Aging Reimagined — New Health Frontiers (mobility, cognition, immune resilience, regenerative medicine).

If you’re building in this space - or know someone who is - don’t miss this!

📅 Deadline: May 15

👉 Learn More and Apply Here: https://linktr.ee/lillygrandchallenge

✅ More Good News ✅

THE GOOD
Clinical Trials

Pfizer's Elrexfio (elranatamab) Ph3 data shows progression-free survival benefit in relapsed/refractory multiple myeloma
Antibody, cancer, bispecific antibody, multiple myeloma, BCMA target - Read more

THE GOOD
Earnings & Finances

GSK's Shingrix strategy shift targeting comorbid patients drives $1.4B Q1 sales, beating analyst forecasts
Vaccine, infectious disease, revenue impact, competitive - Read more

Teva Pharmaceutical beats Q1 estimates, with Austedo leading 41% growth in branded drug sales
Small molecule, neurological, financial, competitive - Read more

AstraZeneca beats Q1 sales expectations at $15.3B, remains confident in $80B 2030 revenue target
Antibody-drug conjugate, oncology, rare disease, financial, strategic - Read more

Regeneron posts $3.6B Q1 revenue, buoyed by Dupixent and Eylea amid first gene therapy approval
Gene therapy, rare disease, monoclonal antibody, financial, revenue impact - Read more

AbbVie shares, guidance rise as Skyrizi and Rinvoq Q1 sales beat analyst expectations
Small molecule, autoimmune, financial, competitive - Read more

Biogen's Leqembi Q1 sales surge 74% as post-Kisunla treatment switches emerge as new growth opportunity
Monoclonal antibody, Alzheimer's disease, competitive, revenue impact - Read more

THE GOOD
Fundraises

Avalyn Pharma raises $300M IPO to develop drugs for hard-to-treat lung diseases
Pulmonary, small molecule, clinical-stage - Read more

EnteroBiotix secures £19M ($25M) to advance microbiome therapy into Phase 2b IBS trial
Microbiome therapeutics, gastrointestinal, clinical-stage, rare disease - Read more

Vivacta Biotechnology closes $50M Series A and A+ financing for in vivo CAR-T therapies
Oncology, autoimmune, cell therapy, in vivo CAR-T, clinical-stage - Read more

THE GOOD
Investments

AstraZeneca restarts £300M ($404M) UK investment after improved drug pricing terms
Strategic, financial, major transaction, operational - Read more

THE GOOD
Mergers & Acquisitions

Teva Pharmaceuticals acquires Emalex Biosciences for $700M to gain near-approval Tourette drug ecopipam
Small molecule, neurological, strategic, major transaction - Read more

Chiesi acquires KalVista Pharmaceuticals for $1.9B, gaining rare disease oral HAE treatment Ekterly
Small molecule, rare disease, strategic, major transaction - Read more

THE GOOD
Strategic Plans

Biogen targets early-stage assets to build next-generation pipeline after Apellis acquisition
RNAi, neurological, strategic, major transaction - Read more

PRESENTED BY YOU?
Get the attention of 2700+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Business Development & Partnerships

GSK drops $100M-backed Mersana STING ADC XMT-2056, ending option deal and removing asset from pipeline
ADC, oncology, strategic, pipeline - Read more

THE BAD
Clinical Trials

AstraZeneca scraps (atuliflapon) after Ph2 failure in moderate-to-severe uncontrolled asthma, FLAP inhibitor dropped from pipeline
Small molecule, respiratory disease, FLAP inhibitor, asthma, leukotriene pathway - Read more

THE BAD
Earnings & Finances

GE HealthCare cuts profit outlook amid rising costs, restructures units and leadership
Medical imaging, diagnostics, financial, operational, strategic - Read more

THE BAD
Regulatory

FDA halts U.S. enrollment in Newron Pharmaceuticals' phase 3 schizophrenia trial after patient death
Small molecule, neurological, regulatory, operational - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

The torrent of biopharma M&A continues - now with AbbVie gaining exclusive right to acquire Kestrel Therapeutics for up to $1.45B. | Gif: natgeochannel on Giphy

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

AstraZeneca's Breztri (budesonide/glycopyrrolate/formoterol fumarate) gains FDA approval for asthma in patients aged 12 and older following Ph3 success
Small molecule, respiratory disease, inhaled corticosteroid, asthma, COPD, fixed-dose combination - Read more

THE GOOD
Business Development & Partnerships

Remepy, Merck KGaA collaborate on app-paired hybrid drug model for rare tumour treatments
Research collaboration, oncology, rare disease, digital health, AI/ML - Read more

Eli Lilly, Profluent Bio partner on AI-designed DNA editing tools for genetic medicines, up to $2.25B milestones
Research collaboration, rare disease, gene therapy, AI/ML, milestone payments, royalties - Read more

Protagonist Therapeutics opts out of US rusfertide profit split, securing $475M from Takeda
Licensing deal, rare disease, small molecule, milestone payments, royalties - Read more

Rocket Pharmaceuticals sells rare pediatric disease priority review voucher for $180M
Rare disease, gene therapy, priority review voucher, hematopoietic stem cell, cardiovascular - Read more

BeOne Medicines, Huahui Health partner on trispecific antibody HH160, $20M upfront, $1.87B milestones
Licensing deal, oncology, antibody, milestone payments, equity investment - Read more

PRESENTED BY NUCLEATE
Apply for the 2026 Lilly Grand Challenge: Aging Reimagined

🚨 Applications are open for the 2026 Lilly Grand Challenge: Aging Reimagined

🔬 $100K in non-dilutive funding (no strings attached)
🏛️ A 2 day pitch at Lilly HQ in Indianapolis (all expenses paid)
🤝 Direct access to Lilly's scientific and venture teams

This year’s focus: Aging Reimagined — New Health Frontiers (mobility, cognition, immune resilience, regenerative medicine).

If you’re building in this space - or know someone who is - don’t miss this!

📅 Deadline: May 15

👉 Learn More and Apply Here: https://linktr.ee/lillygrandchallenge

✅ More Good News ✅

THE GOOD
Clinical Trials

Asgard Therapeutics presents preclinical data on AT-108 cancer immunotherapy ahead of clinical advancement
Gene therapy, cancer, in vivo cell reprogramming, tumor microenvironment, cancer immunotherapy, antigen-presenting cells - Read more

Boehringer Ingelheim's (survodutide) meets Ph3 goals in obesity, showing significant weight loss with muscle preservation
Protein therapy, metabolic, GLP-1 agonist, obesity, MASH, glucagon receptor agonist - Read more

Erasca's (ERAS-0015) Ph1 pan-RAS molecular glue shows 40–62% response rates in RAS-mutant solid tumors
Small molecule, cancer, molecular glue, pancreatic cancer, non-small cell lung cancer, RAS mutation - Read more

Incyte plans vitiligo submission for (povorcitinib) following Ph3 STOP-V1 and STOP-V2 trial success
Small molecule, autoimmune, JAK1 inhibitor, vitiligo, hidradenitis suppurativa - Read more

THE GOOD
Earnings & Finances

Novartis reaffirms $5B Pluvicto peak sales goal despite European label withdrawal and competitive pressures
Radioligand therapy, oncology, regulatory, financial, competitive - Read more

THE GOOD
Fundraises

Coultreon Biopharma raises $125M Series A to advance oral SIK3 autoimmune drug
Autoimmune, small molecule, oral drug, clinical-stage, SIK inhibitor - Read more

Northern Gritstone closes £20M ($27M) additional share commitments, totaling £382M permanent capital
Venture capital, life sciences, deeptech, AI, gene therapy - Read more

Lighthouse Pharmaceuticals closes $12M Series A to advance Alzheimer's disease program LHP588
Clinical-stage, small molecule, Alzheimer disease, neurological, neurodegenerative - Read more

CTIBIOTECH receives €1.25M ($1.47M) from Bpifrance to launch CTIONCOTEST 3D bioprinting platform
Oncology, 3D bioprinting, drug discovery, tissue engineering, cancer, preclinical - Read more

THE GOOD
Mergers & Acquisitions

AbbVie gains exclusive right to acquire Kestrel Therapeutics for up to $1.45B, targeting oral pan-KRAS inhibitor
Acquisition option, oncology, small molecule, milestone payments - Read more

THE GOOD
Regulatory

FDA launches real-time clinical trial data review initiative with AstraZeneca and Amgen in pilot program
Regulatory innovation, operational, strategic, competitive - Read more

Orca Bio's Orca-Q receives FDA RMAT designation for high-risk hematologic malignancies treatment
Allogeneic T-cell therapy, hematologic malignancies, regulatory, strategic - Read more

PRESENTED BY YOU?
Get the attention of 2700+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Clinical Trials

Janux Therapeutics halts JANX008 (masked EGFR/CD3 T-cell engager) Ph1 development in metastatic solid tumors due to insufficient activity
Antibody, cancer, bispecific T-cell engager, solid tumor, EGFR, CD3 - Read more

THE BAD
Earnings & Finances

Novartis Q1 sales dip 5% as generic erosion hits Entresto, radioequivalent competition looms for Lutathera
Radioligand therapy, oncology, financial, competitive, revenue impact - Read more

THE BAD
Lawsuits

GSK's Tesaro loses pre-trial ruling in Jemperli royalty dispute with AnaptysBio
Monoclonal antibody, oncology, competitive, financial - Read more

Revolution Medicines threatens legal action against Erasca over pancreatic cancer drug patent infringement claims
Small molecule, oncology, competitive, financial - Read more

THE BAD
Politics & Policy

Novartis CEO calls for "complete rethink" of Europe's drug pricing policies, warning of delayed medicine access
Drug pricing, regulatory, strategic, competitive, revenue impact - Read more

THE BAD
Regulatory

FDA raises trial design and efficacy concerns for AstraZeneca's camizestrant and Truqap ahead of advisory meeting
Small molecule, oncology, regulatory, competitive - Read more

THE UGLY
Regulatory

FDA alleges Amgen's Tavneos approval was backed by manipulated clinical trial data, calls for withdrawal
Small molecule, autoimmune, regulatory, rare disease - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

Rejuvenate Bio launches crowdfunding campaign to advance gene therapy for aging, chronic diseases. | Gif: GoldenHuckFin on Giphy

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

AstraZeneca's Saphnelo (anifrolumab) autoinjector pen wins FDA approval for systemic lupus erythematosus based on Ph3 results
Antibody, autoimmune, monoclonal antibody, systemic lupus erythematosus, type I interferon receptor, subcutaneous administration - Read more

Novartis' Rhapsido (remibrutinib) receives European Commission approval as first oral BTK inhibitor for chronic spontaneous urticaria
Small molecule, autoimmune, BTK inhibitor, chronic spontaneous urticaria, histamine pathway - Read more

Crinetics Pharmaceuticals' PALSONIFY (paltusotine) receives European Commission approval for acromegaly in adults following Ph3 trials
Small molecule, metabolic, somatostatin receptor agonist, acromegaly, endocrine disorder - Read more

UK MHRA grants marketing authorisation to MSD's Enflonsia for RSV prevention in infants
Monoclonal antibody, infectious disease, regulatory, competitive - Read more

THE GOOD
Business Development & Partnerships

Teikoku Seiyaku, Curedisc sign license agreement for KTP-001 lumbar disc herniation treatment in Japan
Licensing deal, musculoskeletal, recombinant protein, regulatory, commercialization - Read more

HK inno.N, Atomatrix partner to develop AI-driven small molecule non-incretin obesity treatments
Co-development, small molecule, obesity, AI/ML, drug discovery - Read more

Thermo Fisher Scientific divests microbiology business to Astorg for $1.075B
Divestiture, diagnostics, infectious disease, manufacturing, equity investment - Read more

PRESENTED BY NUCLEATE
Apply for the 2026 Lilly Grand Challenge: Aging Reimagined

🚨 Applications are open for the 2026 Lilly Grand Challenge: Aging Reimagined

🔬 $100K in non-dilutive funding (no strings attached)
🏛️ A 2 day pitch at Lilly HQ in Indianapolis (all expenses paid)
🤝 Direct access to Lilly's scientific and venture teams

This year’s focus: Aging Reimagined — New Health Frontiers (mobility, cognition, immune resilience, regenerative medicine).

If you’re building in this space - or know someone who is - don’t miss this!

📅 Deadline: May 15

👉 Learn More and Apply Here: https://linktr.ee/lillygrandchallenge

✅ More Good News ✅

THE GOOD
Clinical Trials

Mundipharma, CorMedix's Rezzayo (rezafungin) meets Ph3 endpoint for invasive fungal disease prevention in allogeneic hematopoietic stem cell transplant patients
Small molecule, infectious disease, antifungal, invasive fungal disease, hematopoietic stem cell transplant - Read more

Oruka Therapeutics' ORKA-001 (orka-001) shows Ph2 promise in plaque psoriasis, achieving total skin clearance in nearly two-thirds of patients
Antibody, autoimmune, monoclonal antibody, psoriasis, IL-23 inhibitor, long-acting therapy - Read more

Veradermics' VDPHL01 (minoxidil) hits Ph3 goal in male pattern baldness, first potential new pill in 30 years
Small molecule, dermatological, oral formulation, male pattern baldness, minoxidil, hair loss - Read more

Intellia Therapeutics' lonvo-z succeeds in Ph3 trial for hereditary angioedema, company begins rolling FDA submission
Gene therapy, rare disease, CRISPR, hereditary angioedema, gene editing - Read more

Keythera Pharmaceuticals' KF-0210 (EP4 receptor antagonist) cuts pain scores 86.7% in Ph2a knee osteoarthritis study
Small molecule, musculoskeletal, EP4 receptor antagonist, osteoarthritis, pain management - Read more

Cantargia's nadunolimab (IL1RAP) shows early Ph1b/2a complete remissions in high-risk myelodysplastic syndrome and acute myelogenous leukemia
Antibody, cancer, monoclonal antibody, myelodysplastic syndrome, acute myeloid leukemia, IL1RAP - Read more

THE GOOD
Fundraises

Rejuvenate Bio launches crowdfunding campaign to advance gene therapy for aging, chronic diseases
Gene therapy, aging, chronic disease, preclinical - Read more

Hemab plans $180M IPO to advance clotting disorder pipeline, including sutacimig
Rare disease, antibody, hematology, clinical-stage - Read more

Fathom Therapeutics raises $47M Series A for quantum chemistry and AI-driven small molecule drug design
AI/ML platform, small molecule, drug discovery, platform-enabled - Read more

Veradermics plans public offering of 3.35M shares for pattern hair loss therapies
Dermatology, hair loss, small molecule, clinical-stage - Read more

THE GOOD
IPOs

Seaport plans $180M IPO to fund depression candidate SPT-300 advancement
Neurological, small molecule, platform technology, depression, clinical-stage - Read more

THE GOOD
Lawsuits

Pfizer settles with Dexcel, Cipla in Vyndamax patent dispute, potentially delaying generic ATTR-CM competition
Small molecule, cardiovascular, competitive, financial - Read more

THE GOOD
Market Reports

UK biotech VC funding rises 17% in Q1 2026, showing recovery signs, but IPO activity remains stagnant
Venture capital, biotech funding, financial, strategic - Read more

THE GOOD
Mergers & Acquisitions

Ligand Pharmaceuticals to acquire Xoma Royalty for $739M, nearly doubling its royalty aggregator portfolio
Royalty aggregation, rare disease, major transaction, strategic - Read more

Eli Lilly to acquire Ajax Therapeutics for up to $2.3B, expanding oncology portfolio with next-gen JAK2 inhibitor
Small molecule, oncology, rare disease, major transaction, strategic - Read more

PRESENTED BY YOU?
Get the attention of 2700+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Clinical Trials

Compass Therapeutics' (tovecimig) Ph2/3 overall survival data raise approvability concerns for biliary tract cancer
Antibody, cancer, bispecific antibody, biliary tract cancer, PD-1, combination therapy - Read more

THE BAD
Earnings & Finances

Astellas relies on five strategic brands to offset projected Xtandi decline in fiscal 2026
Small molecule, oncology, strategic, revenue impact, competitive - Read more

THE BAD
Regulatory

FDA criticizes Incyte over misleading promotional claims for cGVHD drug Niktimvo
Monoclonal antibody, rare disease, regulatory, competitive - Read more

FDA issues warning letters to UCSF, Par Health over environmental monitoring failures
Radiopharmaceutical, sterile injectable, regulatory, operational, manufacturing compliance - Read more

THE BAD
Strategic Plans

Astellas halts (resamirigene bilparvovec) gene therapy, pivots to ASP2957 Ph1/2 for X-linked myotubular myopathy
Gene therapy, rare disease, small molecule, X-linked myotubular myopathy, AAV capsid, autoimmune - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

Sun Pharma to acquire Organon for $12.5B in largest-ever overseas deal by Indian company.

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Arrowhead Pharmaceuticals' Redemplo (plozasiran) gains broader CHMP approval for familial chylomicronemia syndrome without genetic confirmation requirement
Small molecule, metabolic, siRNA, familial chylomicronemia syndrome, APOC3, triglyceride reduction - Read more

EMA recommends approval of Sanofi's tolebrutinib for secondary progressive multiple sclerosis after FDA rejection
Small molecule, neurological, regulatory, strategic - Read more

EU panel recommends Novartis' Itvisma, expanding SMA gene therapy approval beyond infants
Gene therapy, rare disease, regulatory, reformulation - Read more

THE GOOD
Earnings & Finances

Thermo Fisher Scientific beats Q1 expectations with 6% revenue growth, raises 2026 guidance
Biopharma services, financial, major transaction, strategic - Read more

PRESENTED BY NUCLEATE
Apply for the 2026 Lilly Grand Challenge: Aging Reimagined

🚨 Applications are open for the 2026 Lilly Grand Challenge: Aging Reimagined

🔬 $100K in non-dilutive funding (no strings attached)
🏛️ A 2 day pitch at Lilly HQ in Indianapolis (all expenses paid)
🤝 Direct access to Lilly's scientific and venture teams

This year’s focus: Aging Reimagined — New Health Frontiers (mobility, cognition, immune resilience, regenerative medicine).

If you’re building in this space - or know someone who is - don’t miss this!

📅 Deadline: May 15

👉 Learn More and Apply Here: https://linktr.ee/lillygrandchallenge

✅ More Good News ✅

THE GOOD
Fundraises

Avalyn Pharma plans $200M IPO to develop inhaled treatments for pulmonary fibrosis
Pulmonary fibrosis, small molecule, inhaled drug delivery, clinical-stage - Read more

THE GOOD
Lawsuits

Astellas Pharma, MSN Pharmaceuticals amend Myrbetriq settlement and license agreement with $75M upfront payment
Licensing deal, small molecule, royalties, commercialization - Read more

THE GOOD
Market Reports

Guggenheim predicts Travere Therapeutics' Filspari to hit $3.1B peak sales with explosive FSGS launch
Small molecule, rare disease, revenue impact, competitive - Read more

THE GOOD
Mergers & Acquisitions

WCG acquires The Contract Network to streamline AI-driven clinical trial contract and startup workflows
AI technology, clinical trials operations, strategic, major transaction - Read more

Sun Pharma to acquire Organon for $12.5B in largest-ever overseas deal by Indian company
Biosimilar, women's health, strategic, major transaction - Read more

THE GOOD
Product Launches

Johnson & Johnson launches 4 prescription drugs on Trump administration's TrumpRx discounted pharmaceutical website
Small molecule, cardiovascular, metabolic disease, cost reduction, strategic - Read more

THE GOOD
Regulatory

FDA awards national priority vouchers to Compass Pathways, Transcend Therapeutics, and Usona Institute for psychedelic treatments
Small molecule, neurological, regulatory, strategic - Read more

Novartis' Coartem Baby antimalarial receives WHO prequalification, expanding access for newborns weighing 2-5kg
Small molecule, infectious disease, regulatory, strategic - Read more

PRESENTED BY YOU?
Get the attention of 2700+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Earnings & Finances

Daiichi Sankyo shares fall 10% after earnings delay tied to HER3-DXd supply contract losses
Antibody-drug conjugate, oncology, financial, operational - Read more

THE BAD
Lawsuits

CureVac sues Moderna for patent infringement over mRNA technology used in Spikevax COVID-19 vaccine
mRNA vaccine, infectious disease, competitive, financial - Read more

THE BAD
Layoffs

Pfizer plans 100+ layoffs at Ireland's Ringaskiddy plant amid ongoing global cost-cutting campaign
Small molecule, cost reduction, operational, strategic - Read more

THE BAD
Regulatory

Novartis withdraws EU application to broaden Pluvicto's prostate cancer label after regulatory pushback
Radioligand therapy, oncology, competitive, regulatory - Read more

AbbVie's trenibotulinumtoxinE receives FDA complete response letter over manufacturing concerns for glabellar lines
Protein therapy, aesthetics, botulinum toxin, glabellar lines, manufacturing - Read more

THE UGLY
Company Shutdown

Tempero Bio to shut down after serious adverse event halts Phase 2 alcohol use disorder drug TMP-301 development
Small molecule, neurological, mGluR5 modulator, substance use disorder, alcohol use disorder - Read more [Paywall]

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

Kurma Partners closes €215M ($251M) Biofund IV to back around 20 European biotechs. | Gif: desusandmeroonshowtime on Giphy

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Regeneron Pharmaceuticals' Otarmeni wins FDA approval for otoferlin-deficient congenital hearing loss following Ph1/2 success
Gene therapy, hearing loss, monoclonal antibody, otoferlin, OTOF gene, congenital deafness - Read more

THE GOOD
Business Development & Partnerships

Atrium Therapeutics earns $15M milestone from Bristol Myers Squibb under cardiovascular RNA therapy collaboration
Licensing deal, cardiovascular, RNA therapeutics, milestone payments, royalties - Read more

Dogwood Therapeutics, PRIDCor Therapeutics partner on antiviral assets IMC-1 and IMC-2, up to $100M potential payments
Co-development, infectious disease, small molecule, royalties, milestone payments - Read more

PRESENTED BY HAPATUNE X SCIENCE 2 SALES
Don't Get Left Behind
Life Science Marketing & Sales for the 21st Century

Struggling with your sales & marketing stack as you’re selling into biotech & life sciences? We’re here to help with a free webinar.

Come learn the importance of brand establishment, proper segmentation of your target ICP, thought leadership content development, omnichannel approaches to outreach campaigns, and personalized, high-touch outreach.

Presented by Hapatune, a boutique marketing firm for bioprocess and life science companies, and Science 2 Sales, a lead-gen and GTM agency helping companies sell into biotech, life sciences, and pharma.

Grab your spot before it’s all filled out!

✅ More Good News ✅

THE GOOD
Clinical Trials

Novo Nordisk's Rybelsus (semaglutide) meets Ph3 goals in pediatric type 2 diabetes, supporting label expansion filings
Small molecule, metabolic, GLP-1 receptor agonist, type 2 diabetes, pediatric population - Read more

Mozart Therapeutics' MTX-101 (CD8 Treg modulator) shows positive Ph1b interim data in adults with Stage 3 type 1 diabetes
Small molecule, autoimmune, type 1 diabetes, CD8 Treg modulator, immunomodulation, beta cell preservation - Read more

THE GOOD
Earnings & Finances

Sanofi beats Q1 sales expectations with Dupixent up 31%, reaffirms 2026 growth guidance
Monoclonal antibody, autoimmune, financial, competitive, leadership change - Read more

Roche bets on giredestrant and obesity drugs to offset $6.7B biosimilar sales threat through 2030
Small molecule, oncology, obesity, competitive, strategic - Read more

THE GOOD
Fundraises

Kurma Partners closes €215M ($251M) Biofund IV to back around 20 European biotechs
Venture capital, biotech investing, antibody-drug conjugate, obesity - Read more

Celerion receives undisclosed THL Partners investment to expand clinical pharmacology capabilities
CRO, clinical pharmacology, bioanalytical services, Phase 1 studies - Read more

Ferrosa Therapeutics raises $3.5M Seed funding to advance bispecific antibody for anemia of inflammation
Antibody, anemia, autoimmune, preclinical, bispecific - Read more

Gravity Rail raises $2.75M seed funding, AI platform for patient communications
AI/ML platform, patient communication, software platform, services - Read more [Paywall]

THE GOOD
Investments

Evonik invests €80M ($93.6M) in Slovakia facility to boost fermentation capabilities, adding 50 jobs
Fermentation/biotech manufacturing, pharmaceutical ingredients, strategic, major transaction - Read more

THE GOOD
Product Launches

Deerfield launches Prismatiq software to help pharma brand teams manage sales rep content and compliance
Pharma sales software, operational, competitive, strategic - Read more

THE GOOD
Politics & Policy

Regeneron joins White House 'most favored nation' drug pricing deal, pledging Medicaid price reductions aligned with developed nations
Small molecule, cardiovascular, strategic, regulatory, financial - Read more

PRESENTED BY YOU?
Get the attention of 2700+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Approvals & Labels

FDA rejects Grace Therapeutics' GTx-104 (nimodipine) for aneurysmal subarachnoid haemorrhage over CMC concerns after Ph3
Small molecule, neurological, nanoparticle formulation, aneurysmal subarachnoid haemorrhage, nimodipine, cerebral vasospasm - Read more

THE BAD
Earnings & Finances

Roche Q1 sales drop 5% to CHF 14.7B ($18.73B), hurt by strong Swiss franc despite 6% constant-currency growth
Small molecule, oncology, financial, revenue impact - Read more

THE BAD
Regulatory

Unnamed pharma files citizen petition urging FDA to halt public release of drug rejection letters
FDA transparency, regulatory, operational, competitive - Read more

THE BAD
Strategic Plans

Pfizer discontinues Ph1 trial of (PF-08046037), PD-L1-targeting immunostimulatory drug conjugate, across multiple cancers
Antibody, cancer, immunostimulatory drug conjugate, PD-L1, non-small cell lung cancer, TLR7 agonist - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

Merck & Co., Google Cloud partner on enterprise-wide agentic AI transformation, investment valued up to $1B. | Gif: fallontonight on Giphy

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Ipsen's Ojemda (tovorafenib) wins EU approval for relapsed or refractory pediatric low-grade glioma in Ph2
Small molecule, cancer, BRAF inhibitor, pediatric low-grade glioma, brain tumor - Read more

Sanofi's Tzield (teplizumab-mzwv) receives FDA label expansion for stage 3 type 1 diabetes delay in children as young as one
Antibody, autoimmune, monoclonal antibody, type 1 diabetes, pediatric population, CD3 target - Read more

Moderna's mCOMBRIAX (mRNA-1010/mNEXSPIKE) wins European Commission approval for influenza and COVID-19 combination immunization in adults 50 and older
Vaccine, infectious disease, mRNA vaccine, COVID-19, influenza, combination vaccine - Read more

THE GOOD
Business Development & Partnerships

Merck & Co., Google Cloud partner on enterprise-wide agentic AI transformation, investment valued up to $1B
Enterprise partnership, AI/ML, R&D, manufacturing, commercialization - Read more

PRESENTED BY HAPATUNE X SCIENCE 2 SALES
Don't Get Left Behind
Life Science Marketing & Sales for the 21st Century

Struggling with your sales & marketing stack as you’re selling into biotech & life sciences? We’re here to help with a free webinar.

Come learn the importance of brand establishment, proper segmentation of your target ICP, thought leadership content development, omnichannel approaches to outreach campaigns, and personalized, high-touch outreach.

Presented by Hapatune, a boutique marketing firm for bioprocess and life science companies, and Science 2 Sales, a lead-gen and GTM agency helping companies sell into biotech, life sciences, and pharma.

Grab your spot before it’s all filled out!

✅ More Good News ✅

THE GOOD
Clinical Trials

Revolution Medicines' (daraxonrasib) shows Ph2 promise in first-line RAS-mutated pancreatic cancer as Ph3 trial begins enrolling
Small molecule, cancer, RAS inhibitor, pancreatic cancer, combination therapy - Read more

Ionis Pharmaceuticals' (zilganersen) Ph1-3 data show motor stabilization in Alexander disease ahead of FDA priority review
Antisense oligonucleotide, neurological, rare disease, Alexander disease, motor function - Read more

BridgeBio Oncology Therapeutics presents preclinical data for (BBO-11818) pan-KRAS inhibitor in KRAS-mutant solid tumors ahead of Ph1
Small molecule, cancer, KRAS inhibitor, pancreatic cancer, non-small cell lung cancer, colorectal cancer - Read more

OREGA Biotech's IPH5201 (IPH5201) Ph2 interim results show promising pathological complete response in resectable early-stage non-small cell lung cancer
Antibody, cancer, monoclonal antibody, non-small cell lung cancer, CD39 target, combination therapy - Read more

Roche's fenebrutinib (fenebrutinib) Ph3 data shows record-low relapse rates in relapsing multiple sclerosis amid safety scrutiny
Small molecule, neurological, BTK inhibitor, multiple sclerosis, relapsing multiple sclerosis - Read more

THE GOOD
Fundraises

AcuityMD raises $80M to bolster AI platform for medtech commercial operations
AI/ML platform, software platform, medtech, commercial analytics - Read more

Altimmune prices $225M public offering to fund Phase 3 MASH trial
MASH, liver disease, small molecule, clinical-stage - Read more

10x Science raises $4.8M seed round to build AI for molecular-level protein characterization
AI/ML platform, protein characterization, drug discovery, platform technology - Read more

Maze Therapeutics prices $150M equity offering to advance R&D pipeline
Rare disease, small molecule, platform-enabled, preclinical - Read more

THE GOOD
Investments

AbbVie invests $1.4B to build 185-acre Durham, NC production hub, creating 730-plus jobs
Small molecule, immunology, major transaction, operational - Read more

THE GOOD
Mergers & Acquisitions

Amneal acquires Kashiv BioSciences for $1.1B to expand biosimilars pipeline amid market growth
Biosimilar, oncology, major transaction, strategic - Read more

PRESENTED BY YOU?
Get the attention of 2700+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Business Development & Partnerships

Eli Lilly exits Rigel Pharmaceuticals' RIPK1 alliance, forfeiting $835M milestones on two inhibitors
Licensing deal, small molecule, autoimmune, neurological, milestone payments - Read more

THE BAD
Politics & Policy

CMS postpones BALANCE GLP-1 pilot indefinitely, hitting Eli Lilly and Novo Nordisk stocks
GLP-1, obesity, regulatory, revenue impact - Read more

THE BAD
Regulatory

FDA issues warning letter to New Life Pharma after inspectors denied access to GLP-1 manufacturing facility
Small molecule, metabolic disease, regulatory, operational, manufacturing compliance - Read more

FDA extends review of Sanofi's Sarclisa (isatuximab-irfc) subcutaneous biologics license application for multiple myeloma
Antibody, cancer, monoclonal antibody, multiple myeloma, CD38 target, subcutaneous formulation - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

Ray Therapeutics raises $125M Series B for genetic retinal degeneration gene therapy.

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Merck & Co.'s Idvynso (doravirine/islatravir) wins FDA approval for virologically suppressed adults with human immunodeficiency virus following Ph3 success
Small molecule, infectious disease, combination therapy, HIV, reverse transcriptase inhibitor - Read more

THE GOOD
Business Development & Partnerships

Foundation Medicine, Bristol Myers Squibb expand collaboration on FoundationOne CDx for MTAP deletion detection
Co-development, oncology, diagnostics, biomarkers, companion diagnostic - Read more

Crown Bioscience, Turbine partner to integrate AI-driven virtual assays with tumor organoid validation in translational oncology
Research collaboration, oncology, AI/ML, drug discovery, diagnostics - Read more

GC Biopharma, Galux collaborate on AI-designed antibody therapeutics targeting autoimmune diseases
Research collaboration, autoimmune, AI/ML, antibody, co-development - Read more

PRESENTED BY HAPATUNE X SCIENCE 2 SALES
Don't Get Left Behind
Life Science Marketing & Sales for the 21st Century

Struggling with your sales & marketing stack as you’re selling into biotech & life sciences? We’re here to help with a free webinar.

Come learn the importance of brand establishment, proper segmentation of your target ICP, thought leadership content development, omnichannel approaches to outreach campaigns, and personalized, high-touch outreach.

Presented by Hapatune, a boutique marketing firm for bioprocess and life science companies, and Science 2 Sales, a lead-gen and GTM agency helping companies sell into biotech, life sciences, and pharma.

Grab your spot before it’s all filled out!

✅ More Good News ✅

THE GOOD
Clinical Trials

AstraZeneca's Ultomiris (ravulizumab) meets primary endpoint in Ph3 trial for immunoglobulin A nephropathy
Antibody, autoimmune, monoclonal antibody, IgA nephropathy, complement inhibitor, rare disease - Read more

BioAge Labs' BGE-102 (BGE-102) shows Ph1 promise in cardiovascular risk via NLRP3 inhibition, Ph2 planned
Small molecule, cardiovascular, NLRP3 inhibitor, atherosclerotic cardiovascular disease, inflammation - Read more

Roche's Enspryng (satralizumab) meets Ph3 primary endpoint in myelin oligodendrocyte glycoprotein antibody-associated disease, global submissions planned
Antibody, autoimmune, monoclonal antibody, MOGAD, IL-6 receptor, neurological - Read more

Dayspring Pharma's CG2001 (minoxidil/finasteride) meets Ph2 primary endpoint in androgenetic alopecia in Chinese adult men
Small molecule, dermatological, combination therapy, androgenetic alopecia, minoxidil, finasteride - Read more

Johnson & Johnson and Legend Biotech's Carvykti (ciltacabtagene autoleucel) shows Ph2 promise in high-risk smoldering multiple myeloma
Cell therapy, cancer, CAR-T, multiple myeloma, smoldering multiple myeloma, BCMA target - Read more

THE GOOD
Company Launches

Flagship Pioneering launches Serif Biomedicines with $50M to develop novel modified DNA genetic medicines
Gene therapy, rare disease, financial, strategic - Read more

Tortugas Neuroscience debuts with $106M seed and Series A for CNS disorders
Neurological, small molecule, clinical-stage, schizophrenia, epilepsy - Read more

THE GOOD
Fundraises

Ray Therapeutics raises $125M Series B for genetic retinal degeneration gene therapy
Gene therapy, ophthalmology, rare disease, retinal degeneration, clinical-stage - Read more

Lumira Ventures holds first closing of Fund V, targeting $200M for biotech and medtech
Venture capital, biotechnology, medical device, healthcare investment - Read more

Spruce Biosciences prices $60M public offering for neurological disorder therapies development
Neurological, rare disease, clinical-stage, small molecule - Read more

THE GOOD
Product Launches

Amazon One Medical launches all-in-one GLP-1 weight management programme bundling primary care, pharmacy, and virtual care
GLP-1, obesity, competitive, strategic - Read more

THE GOOD
Strategic Plans

Vidac Pharma Holdings evaluates continental European expansion into France, Germany, and Switzerland via spin-off entity
Small molecule, oncology, strategic, operational - Read more

PRESENTED BY YOU?
Get the attention of 2700+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Clinical Trials

Merck & Co.’s Welireg (belzutifan) Ph3 trial misses dual endpoints in first-line clear cell renal cell carcinoma
Small molecule, cancer, combination therapy, renal cell carcinoma, HIF-2α inhibitor, PD-1 inhibitor - Read more

Novartis drops two Ph3 (abelacimab) programs for cancer-related thrombosis after inferior efficacy observed
Small molecule, cardiovascular, anticoagulant, factor XI inhibitor, atrial fibrillation, cancer-associated thrombosis - Read more [Paywall]

THE BAD
Layoffs

Replimune cuts 224 Massachusetts jobs after FDA's second rejection of melanoma drug RP1
Oncolytic virus, oncology, regulatory, cost reduction - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

Eli Lilly acquires Kelonia Therapeutics for up to $7B to expand in vivo CAR-T capabilities. | Gif: fallontonight on Giphy

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Specialised Therapeutics' ZEPZELCA (lurbinectedin) plus atezolizumab approved in Australia and Singapore for extensive-stage small cell lung cancer
Small molecule, cancer, combination therapy, small cell lung cancer, PD-L1 inhibitor, first-line maintenance - Read more

GSK's Blenrep (belantamab mafodotin) receives China NMPA approval for relapsed/refractory multiple myeloma based on Ph3 data
Antibody-drug conjugate, cancer, multiple myeloma, BCMA target, combination therapy - Read more

ClearPoint Neuro receives Health Canada approval for Neuro Navigation System, expanding drug delivery platform globally
Cell and gene therapy, neurological, strategic, operational - Read more

THE GOOD
Business Development & Partnerships

Biogen, TJ Biopharma expand partnership for China rights to felzartamab, $100M upfront, $850M biobucks
Licensing deal, autoimmune, rare disease, antibody, milestone payments, royalties - Read more

Genflow Biosciences, Acuitas Therapeutics collaborate on LNP delivery for SIRT6 mRNA gene therapy, fully funded by Acuitas
Research collaboration, gene therapy, drug delivery, rare disease, mRNA - Read more

Nxera Pharma receives $10M milestone from AbbVie in neurological disease GPCR drug discovery collaboration
Research collaboration, neurological, small molecule, milestone payments, drug discovery, royalties - Read more

LIR Life Sciences, Resilience BioSciences collaborate on preclinical drug research for $5,000 monthly
Research collaboration, drug discovery, small molecule, preclinical research, non-opioid therapeutics - Read more

SynSmart, Amporin Pharmaceuticals collaborate to develop small molecule therapeutics for degenerative diseases
Research collaboration, small molecule, neurological, rare disease, drug discovery - Read more

PRESENTED BY HAPATUNE X SCIENCE 2 SALES
Don't Get Left Behind
Life Science Marketing & Sales for the 21st Century

Struggling with your sales & marketing stack as you’re selling into biotech & life sciences? We’re here to help with a free webinar.

Come learn the importance of brand establishment, proper segmentation of your target ICP, thought leadership content development, omnichannel approaches to outreach campaigns, and personalized, high-touch outreach.

Presented by Hapatune, a boutique marketing firm for bioprocess and life science companies, and Science 2 Sales, a lead-gen and GTM agency helping companies sell into biotech, life sciences, and pharma.

Grab your spot before it’s all filled out!

✅ More Good News ✅

THE GOOD
Clinical Trials

AstraZeneca's (tozorakimab) meets primary endpoint in Ph3 trial for chronic obstructive pulmonary disease
Antibody, respiratory disease, monoclonal antibody, COPD, IL-33 inhibitor - Read more

Sanofi's Nuvaxovid outperforms Moderna's mNexspike in Ph4 tolerability trial for coronavirus disease 2019
Vaccine, infectious disease, protein subunit vaccine, mRNA vaccine, COVID-19, tolerability - Read more

Nektar Therapeutics' (rezpegaldesleukin) shows extended hair regrowth in Ph2 alopecia areata study at 52 weeks
Protein therapy, autoimmune, interleukin, alopecia areata, eczema - Read more

Kyverna Therapeutics' (mivocabtagene autoleucel) shows durable Ph2 responses in generalised myasthenia gravis at one year
Cell therapy, autoimmune, CAR-T, myasthenia gravis, neuromuscular disease - Read more

Lytix Biopharma's ruxotemitide (LTX-315) shows Ph2 promise in PD-1/PD-L1 refractory advanced melanoma with pembrolizumab combination
Small molecule, cancer, intratumoral therapy, melanoma, PD-1/PD-L1 refractory, combination therapy - Read more

Novo Nordisk's (etavopivat) meets Ph3 primary endpoint, reducing vaso-occlusive crises in sickle cell disease
Small molecule, blood disorder, pyruvate kinase activator, sickle cell disease, gene therapy - Read more

THE GOOD
Fundraises

Pulnovo Medical raises $100M, advancing pulmonary hypertension and heart failure interventional therapies
Pulmonary hypertension, cardiovascular, medical device, clinical-stage - Read more

ViewsML raises $4.9M seed funding to accelerate AI-driven virtual biomarker staining platform
AI/ML platform, biomarker discovery, digital pathology, oncology, platform-enabled - Read more

Odyssey Therapeutics files for IPO, targeting autoimmune and inflammatory disease treatments
Autoimmune, small molecule, inflammatory disease, clinical-stage - Read more

THE GOOD
Investments

Boehringer Ingelheim invests £150M ($202.2M) to open AI drug R&D hub in London over 10 years
AI/machine learning, drug discovery, strategic, major transaction - Read more

THE GOOD
Mergers & Acquisitions

Roche acquires SAGA Diagnostics for $595M to bolster Foundation Medicine's MRD diagnostics portfolio
Diagnostics, oncology, strategic, major transaction - Read more

Eli Lilly acquires Kelonia Therapeutics for up to $7B to expand in vivo CAR-T capabilities
CAR-T, oncology, strategic, major transaction - Read more

THE GOOD
Regulatory

Trump signs executive order to accelerate psychedelic therapy development, boosting Compass Pathways shares 25%
Psychedelic therapy, mental health, regulatory, financial - Read more

PRESENTED BY YOU?
Get the attention of 2700+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Clinical Trials

Agenus, MiNK Therapeutics' botensilimab-balstilimab-agenT-797 cocktail records 0% response rate in Ph2 gastroesophageal adenocarcinoma trial
Cell therapy, cancer, antibody, combination therapy, gastroesophageal adenocarcinoma, iNKT cell therapy - Read more

Arcus' domvanalimab (anti-TIGIT) Ph3 trial in non-small-cell lung cancer discontinued for futility
Antibody, cancer, monoclonal antibody, non-small cell lung cancer, TIGIT, PD-1 inhibitor - Read more

THE BAD
Lawsuits

Judge rejects Bayer's bid to block J&J's Erleada survival claims over Nubeqa in prostate cancer dispute
Small molecule, oncology, competitive, regulatory - Read more

THE BAD
Layoffs

Bristol Myers Squibb cuts 206 more New Jersey jobs amid ongoing $2B cost-reduction restructuring effort
Operational, cost reduction, financial - Read more

THE BAD
Regulatory

Theramex exits UK pharma self-regulatory body after systemic compliance failures and public reprimand
Small molecule, women's health, regulatory, operational, compliance - Read more

Passage Bio shares plunge 37% after FDA demands randomized trial for FTD gene therapy PBFT02
Gene therapy, neurological, regulatory, strategic, rare disease - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here

Former Genentech leader unveils Synthetic Design Lab, developing adaptive "smart" ADC cancer drugs.

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Merck & Co.'s Enflonsia (clesrovimab) receives EU approval for infant respiratory syncytial virus lower respiratory tract disease prevention
Antibody, infectious disease, monoclonal antibody, RSV, infant population - Read more

THE GOOD
Clinical Trials

Samsung Bioepis' OBODENCE (denosumab) shows consistent Ph3 efficacy across osteoporosis patient subgroups
Protein therapy, metabolic, biosimilar, osteoporosis, denosumab, RANK ligand inhibitor - Read more

Monopar Therapeutics' ALXN1840 (tiomolibdate choline) shows greater neurologic benefit vs standard of care in Ph3 Wilson disease trial
Small molecule, neurological, Wilson disease, copper chelation, metabolic disorder - Read more

Merck & Co. unveils Ph1/Ph2 data for MK-2010 (MK-2010), PD-1xVEGF bispecific, in non-small cell lung cancer
Antibody, cancer, bispecific antibody, non-small cell lung cancer, PD-1, VEGF - Read more

Novo Nordisk's (semaglutide) shows better lean mass preservation over Eli Lilly's (tirzepatide) in observational body composition study
Small molecule, metabolic, GLP-1 agonist, obesity, body composition, semaglutide - Read more

Kura Oncology's darlifarnib (KO-2806) shows 44% response rate in Ph1 clear cell renal cell carcinoma cabozantinib-pretreated patients
Small molecule, cancer, renal cell carcinoma, farnesyl transferase inhibitor, VEGFR inhibitor, combination therapy - Read more

PRESENTED BY HAPATUNE X SCIENCE 2 SALES
Don't Get Left Behind:
Life Science Marketing & Sales for the 21st Century

Struggling with your sales & marketing stack as you’re selling into biotech & life sciences? We’re here to help with a free webinar.

Come learn the importance of brand establishment, proper segmentation of your target ICP, thought leadership content development, omnichannel approaches to outreach campaigns, and personalized, high-touch outreach.

Presented by Hapatune, a boutique marketing firm for bioprocess and life science companies, and Science 2 Sales, a lead-gen and GTM agency helping companies sell into biotech, life sciences, and pharma.

Grab your spot before it’s all filled out!

✅ More Good News ✅

THE GOOD
Company Launches

Former Genentech leader unveils Synthetic Design Lab, developing adaptive "smart" ADC cancer drugs
Antibody-drug conjugate, oncology strategic - Read more

THE GOOD
Fundraises

Orthogon Therapeutics raises additional $11M, advancing polyomavirus-focused drug discovery platform
Infectious disease, small molecule, antiviral, transplant, platform technology - Read more

Biovac Institute raises $108M to expand Cape Town vaccine facility, targeting 400M doses
Vaccine, infectious disease, major transaction, operational - Read more

THE GOOD
Lawsuits

Teva wins appeal reinstating $177M patent infringement verdict against Eli Lilly over migraine drugs
Monoclonal antibody, neurological, competitive, revenue impact - Read more

THE GOOD
Mergers & Acquisitions

UCB to acquire Neurona Therapeutics for up to $1.2B, expanding into seizure cell therapy
Cell therapy, epilepsy, strategic, major transaction - Read more

PRESENTED BY YOU?
Get the attention of 2700+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email hello@tldrbio.tech

THE BAD
Regulatory

FDA marks first-year progress on animal testing roadmap, but experts warn full transition remains years away
New approach methodologies, preclinical safety, regulatory, operational, strategic - Read more

RFK Jr. defends FDA's Makary, backs Replimune RP1 rejection, claims pharma controls congress and media
Oncolytic immunotherapy, oncology, regulatory, competitive - Read more

THE UGLY
Regulatory

FDA vet Pazdur warns of political influence, staff anxiety, and eroding regulatory firewall at agency
Regulatory oversight, oncology, operational, political influence - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here